A trilogy of primary prevention statin trials. Panel discussion.

[1]  M. Sabatine,et al.  Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[2]  S. Yamashita,et al.  Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. , 2000, Atherosclerosis.

[3]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[4]  S. Yamashita,et al.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[6]  Y. Ouchi,et al.  Serum lipid survey and its recent trend in the general Japanese population in 2000. , 2005, Journal of atherosclerosis and thrombosis.

[7]  O. Wiklund,et al.  Cholesterol reduction and clinical benefit. Are there limits to our expectations? , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[9]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[10]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[11]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[12]  R. Westendorp,et al.  TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia , 2005, European Journal of Human Genetics.